Merck-Medco switching patients from Zestoretic to Prinizide, APhA's Knowlton tells FDA.
• By The Pink Sheet
MERCK-MEDCO SWITCHING PATIENTS FROM ZESTORETIC TO PRINIZIDE, according to an example of prescription drug switch programs detailed by American Pharmaceutical Association President Calvin Knowlton at FDA's public hearing on promotions to managed care Oct. 19-20. Knowlton said pharmacists have been objecting to a "prescription change authorization notification" sent by Medco's PAID Prescriptions to switch patients from Zeneca's antihypertensive/diuretic Zestoretic to Merck's Prinizide.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Generative artificial intelligence tools, such as ChatGPT, have “democratized” AI, and contract research organizations are wholeheartedly embracing these tools, given their focus on efficiency, says Stephen Pyke, who chairs the AI committee at the Association of Clinical Research Organizations.